Device Trial Radar · NCT06045572
Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
May 1, 2027
Primary completion
May 1, 2027
Study completion May 1, 2028
Sponsor
- Lead sponsor
- Galzu Institute of Research, Teaching, Science and Applied TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hospital Santa Casa de Misericordia de Campos; Hospital Escola Alvaro Alvim; Universidade Estadual do Norte Fluminense (UENF)
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
When we talk about early identification, we are talking about an ALREADY EXISTING INJURY, triggering a change in the patient's quality of life and a projection of future costs for the health system. INNOVATIVE ASPECT: While screening mammography identifies an existing lesion, VTM could: Make an early diagnosis before the formation of a visible or palpable tumor mass; Check the metabolic activity in suspicious lesions identified by other diagnostic methods; Demarcate tumor range and tumor similarity from a distance in breast cancer. Regarding the Risk x Benefit:There are no medications incorporated, associated or administered by the equipment; There is no ionizing radiation incorporated or delivered by the equipment; There are no contraindications for the use of the equipment by the patient (Non-ionizing infrared radiation, without contrast or contact); Audience destined to operate the equipment: Physician / Radiologist with training Therefore, the research in question is of great relevance for such a debilitating health problem for the patient and for the health system.
Conditions
- Breast Cancer Female
Interventions
VTM examination and breast biopsyDevice
VTM examination performed by a radiologist, at the MART (Metabolic Activity in Real-Time) station, using the SaMD Mart 2.0, according to the inspection protocol to identify breast alterations and/or suspicious images to be biopsied for validation by genetic tests and histology / immunohistochemistry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Concordance of the diagnosis of abnormality during the VTM exam in relation to the standard exam (mammography);Time frame: [D2, approximately 60 days]
- Frequency of non-visible vascular identification:Time frame: [D2, approximately 60 days]
- Frequency of identifying non-visible texturesTime frame: [D2, approximately 60 days]
2 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.